Opinion: The public science behind the ‘Merck’ Ebola vaccine
The private sector promised much and delivered little on the recently approved Ebola vaccine.
The U.S. Food and Drug Administration recently approved an important vaccine against Ebola, five years after an epidemic in West Africa killed 11,310 people and after more than 2,200 have died of it in the Democratic Republic of Congo in the last 18 months.
Alex Azar, who heads the U.S. Department of Health and Human Services, quickly congratulated his department’s funding and “” for the vaccine, which is called Ervebo. As recently , the reality is quite different: Canadian public institutions and funding
